Intellectual property attorneys discuss the clarified requirements for when state failure-to-warn claims are pre-empted by FDA regulations after the Supreme Court Merck case.
Chad Watson
Advertisement
Articles by Chad Watson
Advertisement
Latest Updated Articles
- Clearing Up ‘Clear Evidence’ and Implications for Labeling Post-Merck Decision
Published: May 23rd 2019 | Updated:
Advertisement
Advertisement
Trending on PharmExec
1
Investors Have Questions About GLP-1 Drug Prices Ahead of Eli Lilly and Novo Quarterly Statements: Report
2
Thermo Fisher Enters $8.8 Billion Definitive Agreement to Acquire Clario Holdings
3
FDA Announces New Biosimilar-Targeted Draft Guidance
4
Lilly Forms Partnership with NVIDIA to Create AI Supercomputer
5
